Pituitary carcinomas and aggressive pituitary tumours: merits and pitfalls of temozolomide treatment
Open Access
- 8 March 2012
- journal article
- review article
- Published by Wiley in Clinical Endocrinology
- Vol. 76 (6) , 769-775
Abstract
Summary: Pituitary carcinomas are rare, accounting for about 0·2% of all pituitary tumours. They represent a challenge to clinical practice in both diagnosis and treatment. They may present initially as typical pituitary adenomas, with a delayed appearance of aggressive signs, or as aggressive tumours from the outset. Predicting the pituitary tumour behaviour remains difficult: increased mitotic, Ki‐67 and P53 indices might be associated with tumour aggression. The treatment of pituitary carcinomas and aggressive pituitary tumours includes surgery, adjuvant medical treatment, external beam radiotherapy and chemotherapy. Until recently, the treatment of pituitary carcinomas was mainly palliative and did not seem to increase overall survival. Recent case reports have detailed the successful use of temozolomide, an orally administered alkylating agent used to treat malignant gliomas, in the management of pituitary carcinomas and aggressive pituitary tumours. The outcome of treatment might depend on the expression of O 6 ‐methylguanine‐DNA methyltransferase (MGMT), a DNA repair enzyme that potentially interferes with drug efficacy. This review describes the clinical presentation and response to temozolomide in 44 patients with pituitary carcinomas or aggressive pituitary tumours reported in the literature. The results suggest that temozolomide should be considered a drug of major importance in the therapeutic algorithm of aggressive pituitary tumours and pituitary carcinomas. Because of the inconsistency of published data, MGMT expression should probably not be taken as a reason to deny these patients the potential benefit of temozolomide treatment, taking into account the paucity of other available treatments.Keywords
This publication has 65 references indexed in Scilit:
- Aggressive pituitary tumours: the role of temozolomide and the assessment of MGMT statusEuropean Journal of Clinical Investigation, 2011
- Integrated Genomic Profiling Identifies Loss of Chromosome 11p Impacting Transcriptomic Activity in Aggressive Pituitary PRL TumorsBrain Pathology, 2011
- Proliferation markers of human pituitary tumors: Contribution of a genome-wide transcriptome approachMolecular and Cellular Endocrinology, 2010
- Differential gene expression profiles of invasive and non-invasive non-functioning pituitary adenomas based on microarray analysisEndocrine-Related Cancer, 2010
- Temozolomide (Temodar®) and capecitabine (Xeloda®) treatment of an aggressive corticotroph pituitary tumorPituitary, 2009
- Low O6‐methylguanine‐DNA methyltransferase (MGMT) expression and response to temozolomide in aggressive pituitary tumoursClinical Endocrinology, 2009
- Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trialThe Lancet Oncology, 2009
- USE OF TEMOZOLOMIDE IN AGGRESSIVE PITUITARY TUMORSNeurosurgery, 2009
- New (alternative) temozolomide regimens for the treatment of gliomaNeuro-Oncology, 2009
- A diagnostic marker set for invasion, proliferation, and aggressiveness of prolactin pituitary tumorsEndocrine-Related Cancer, 2007